Figure 1: Disease progression relative to immunological ANXA7 expression (129 patients). The percent of ANXA7 positive samples are plotted against different stages of ovarian cancer starting from normal ovary (8 specimens); Brenner tumor (3 specimens); endometriod carcinoma (34 specimens); mucinous ovarian cancer (12 specimens); serous cystadenocarcinoma (44 specimens) and ovarian cancer not otherwise specified (28 specimens). The ANX7 positivity decreases with disease progression.